PanGen Biotech Statistics

Total Valuation

PanGen Biotech has a market cap or net worth of KRW 81.91 billion. The enterprise value is 65.75 billion.

Market Cap	81.91B
Enterprise Value	65.75B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

PanGen Biotech has 13.49 million shares outstanding. The number of shares has increased by 10.08% in one year.

Current Share Class	13.49M
Shares Outstanding	13.49M
Shares Change (YoY)	+10.08%
Shares Change (QoQ)	+5.58%
Owned by Insiders (%)	4.06%
Owned by Institutions (%)	n/a
Float	6.36M

Valuation Ratios

The trailing PE ratio is 32.78.

PE Ratio	32.78
Forward PE	n/a
PS Ratio	5.17
PB Ratio	2.78
P/TBV Ratio	2.85
P/FCF Ratio	19.55
P/OCF Ratio	17.25
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.24, with an EV/FCF ratio of 15.69.

EV / Earnings	28.62
EV / Sales	4.15
EV / EBITDA	16.24
EV / EBIT	25.39
EV / FCF	15.69

Financial Position

The company has a current ratio of 6.10, with a Debt / Equity ratio of 0.03.

Current Ratio	6.10
Quick Ratio	4.25
Debt / Equity	0.03
Debt / EBITDA	0.22
Debt / FCF	0.21
Interest Coverage	11.85

Financial Efficiency

Return on equity (ROE) is 9.92% and return on invested capital (ROIC) is 6.55%.

Return on Equity (ROE)	9.92%
Return on Assets (ROA)	5.21%
Return on Invested Capital (ROIC)	6.55%
Return on Capital Employed (ROCE)	8.00%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.51
Inventory Turnover	1.24

Taxes

In the past 12 months, PanGen Biotech has paid 73.53 million in taxes.

Income Tax	73.53M
Effective Tax Rate	3.10%

Stock Price Statistics

The stock price has increased by +40.35% in the last 52 weeks. The beta is -0.06, so PanGen Biotech's price volatility has been lower than the market average.

Beta (5Y)	-0.06
52-Week Price Change	+40.35%
50-Day Moving Average	6,286.80
200-Day Moving Average	5,636.03
Relative Strength Index (RSI)	46.03
Average Volume (20 Days)	52,602

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PanGen Biotech had revenue of KRW 15.86 billion and earned 2.30 billion in profits. Earnings per share was 185.15.

Revenue	15.86B
Gross Profit	6.42B
Operating Income	2.59B
Pretax Income	2.37B
Net Income	2.30B
EBITDA	4.05B
EBIT	2.59B
Earnings Per Share (EPS)	185.15

Full Income Statement

Balance Sheet

The company has 17.05 billion in cash and 886.92 million in debt, giving a net cash position of 16.16 billion or 1,197.62 per share.

Cash & Cash Equivalents	17.05B
Total Debt	886.92M
Net Cash	16.16B
Net Cash Per Share	1,197.62
Equity (Book Value)	29.49B
Book Value Per Share	2,233.82
Working Capital	23.07B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.75 billion and capital expenditures -556.82 million, giving a free cash flow of 4.19 billion.

Operating Cash Flow	4.75B
Capital Expenditures	-556.82M
Free Cash Flow	4.19B
FCF Per Share	310.56

Full Cash Flow Statement

Margins

Gross margin is 40.48%, with operating and profit margins of 16.33% and 14.49%.

Gross Margin	40.48%
Operating Margin	16.33%
Pretax Margin	14.95%
Profit Margin	14.49%
EBITDA Margin	25.53%
EBIT Margin	16.33%
FCF Margin	26.43%

Dividends & Yields

PanGen Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.08%
Shareholder Yield	n/a
Earnings Yield	2.80%
FCF Yield	5.12%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

PanGen Biotech has an Altman Z-Score of 4.79 and a Piotroski F-Score of 7.

Altman Z-Score	4.79
Piotroski F-Score	7